Current Molecularly Targeting Therapies in NSCLC and Melanoma

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Current Molecularly Targeting Therapies in NSCLC and Melanoma



Anti-Cancer Agents in Medicinal Chemistry, 15(7): 856-868.

Author(s): Supriya Rajanna, Ichwaku Rastogi, Luke Wojdyla, Hiroko Furo, Agnes Kulesza, Leo Lin, Bonnie Sheu, Mark rakes, Marko Ivanovich and Neelu Puri.

Affiliation: University of Illinois College of Medicine at Rockford, 1601 Parkview Avenue, Rockford, IL, 61107, USA.

Abstract

Surgery, radiation therapy, and chemotherapy are the traditional options to control tumor progression. However, these strategies are fraught with harmful side effects and are ineffective in metastatic and advanced cancers. Biomarkers that are overexpressed in cancers and are involved in cell growth, proliferation, migration, and survival have recently become the focus of new molecular targeting therapies. Novel therapies targeting biomarkers have roles in tumorigenesis that are overexpressed in cancers may be more efficacious and less toxic in comparison to traditional therapies. These therapies include the use of tyrosine kinase inhibitors and monoclonal antibodies for the treatment of cancer. However, the efficacy of these therapies is limited due to the development of drug resistance after prolonged treatment. Current research is focused on understanding mechanisms of resistance to overcome the barriers limiting the use of these targeting therapies in the treatment of cancer. In this review, we will discuss the clinical status of tyrosine kinase inhibitors and monoclonal antibodies against several prevalent biomarkers that are candidates for therapy in non-small cell lung cancer (NSCLC) and melanoma.




Keywords:

Melanoma, monoclonal antibodies, NSCLC, tyrosine kinase inhibitor.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 15
Issue Number: 7
First Page: 856
Last Page: 868
Page Count: 13
DOI: 10.2174/1871520615666150202100130
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science